XLO

Company Overview — What Does Xilio Therapeutics, Inc. Do?

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts. Xilio Therapeutics, Inc. (XLO) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO René Russo and employs approximately 70 people. With a market capitalization of $49M, XLO is one of the notable companies in the Healthcare sector.

Xilio Therapeutics, Inc. (XLO) Stock Rating — Reduce (April 2026)

As of April 2026, Xilio Therapeutics, Inc. receives a Reduce rating with a composite score of 29.6/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.XLO ranks #3,235 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Xilio Therapeutics, Inc. ranks #488 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

XLO Stock Price and 52-Week Range

Xilio Therapeutics, Inc. (XLO) currently trades at $8.51. The stock lost $0.05 (0.6%) in the most recent trading session. The 52-week high for XLO is $8.09, which means the stock is currently trading 5.2% from its annual peak. The 52-week low is $0.46, putting the stock 1742.8% above its annual trough. Recent trading volume was 13K shares, suggesting relatively thin trading activity.

Is XLO Overvalued or Undervalued? — Valuation Analysis

Xilio Therapeutics, Inc. (XLO) carries a value factor score of 11/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.39x, versus the sector average of 2.75x. The price-to-sales ratio is 1.52x, compared to 1.66x for the average Healthcare stock.

At current multiples, Xilio Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Xilio Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Xilio Therapeutics, Inc. (XLO) earns a quality factor score of 13/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -168.5%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -38.4% versus the sector average of -33.1%.

On a margin basis, Xilio Therapeutics, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -328.2% (sector: -66.1%). Net profit margin stands at -338.4%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 708.9% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

XLO Debt, Balance Sheet, and Financial Health

Xilio Therapeutics, Inc. has a debt-to-equity ratio of 339.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 2.58x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $104M.

XLO has a beta of -1.48, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Xilio Therapeutics, Inc. is 31/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Xilio Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Xilio Therapeutics, Inc. reported revenue of $32M and earnings per share (EPS) of $-4.19. Net income for the quarter was $-59M. Gross margin was 100.0%. Operating income came in at $-45M.

In FY 2025, Xilio Therapeutics, Inc. reported revenue of $44M and earnings per share (EPS) of $-4.19. Net income for the quarter was $-35M. Revenue grew 589.9% year-over-year compared to FY 2024. Operating income came in at $-42M.

In Q3 2025, Xilio Therapeutics, Inc. reported revenue of $19M and earnings per share (EPS) of $-0.11. Net income for the quarter was $-16M. Revenue grew 742.5% year-over-year compared to Q3 2024. Operating income came in at $-2M.

In Q2 2025, Xilio Therapeutics, Inc. reported revenue of $8M and earnings per share (EPS) of $-0.16. Net income for the quarter was $-16M. Revenue grew 243.0% year-over-year compared to Q2 2024. Operating income came in at $-14M.

Over the past 8 quarters, Xilio Therapeutics, Inc. has demonstrated a growth trajectory, with revenue expanding from $2M to $32M. Investors analyzing XLO stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

XLO Dividend Yield and Income Analysis

Xilio Therapeutics, Inc. (XLO) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

XLO Momentum and Technical Analysis Profile

Xilio Therapeutics, Inc. (XLO) has a momentum factor score of 48/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 20/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 69/100 reflects moderate short selling activity.

XLO vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Xilio Therapeutics, Inc. (XLO) ranks #488 out of 838 stocks based on the Blank Capital composite score. This places XLO in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing XLO against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full XLO vs S&P 500 (SPY) comparison to assess how Xilio Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

XLO Next Earnings Date

No upcoming earnings date has been announced for Xilio Therapeutics, Inc. (XLO) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy XLO? — Investment Thesis Summary

The quantitative profile for Xilio Therapeutics, Inc. suggests caution. The quality score of 13/100 flags below-average profitability. The value score of 11/100 indicates premium valuation. High volatility (stability score 31/100) increases portfolio risk.

In summary, Xilio Therapeutics, Inc. (XLO) earns a Reduce rating with a composite score of 29.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on XLO stock.

Related Resources for XLO Investors

Explore more research and tools: XLO vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare XLO head-to-head with peers: XLO vs AZN, XLO vs SLGL, XLO vs VMD.